CY1120403T1 - Ανταγωνιστες trpm8 - Google Patents
Ανταγωνιστες trpm8Info
- Publication number
- CY1120403T1 CY1120403T1 CY20181100717T CY181100717T CY1120403T1 CY 1120403 T1 CY1120403 T1 CY 1120403T1 CY 20181100717 T CY20181100717 T CY 20181100717T CY 181100717 T CY181100717 T CY 181100717T CY 1120403 T1 CY1120403 T1 CY 1120403T1
- Authority
- CY
- Cyprus
- Prior art keywords
- trpm8
- compounds
- competitors
- irritable
- neurodegeneration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/40—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/42—One oxygen atom attached in position 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Η εφεύρεση αφορά σε ενώσεις που δρουν ως εκλεκτικοί ανταγωνιστές του μέλους 8 της υποοικογένειας Μ του Δυναμικού διαύλου κατιόντος Παροδικού Υποδοχέα (TRPM8) και που έχουν τον τύπο (I). Οι εν λόγω ενώσεις είναι χρήσιμες στη θεραπεία ασθενειών που συνδυάζονται με δραστικότητα του TRPM8 όπως πόνου, φλεγμονής, ισχαιμίας, νευροεκφυλισμού, συμφόρησης, ψυχιατρικών διαταραχών, κνησμού, ασθενειών ευερέθιστου εντέρου, διεγειρόμενων ή/και επιδεινούμενων από το ψύχος αναπνευστικών διαταραχών και ουρολογικών διαταραχών.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11194365.0A EP2606888A1 (en) | 2011-12-19 | 2011-12-19 | Trpm8 antagonists |
EP12178327 | 2012-07-27 | ||
EP12812229.8A EP2793883B1 (en) | 2011-12-19 | 2012-12-19 | Trpm8 antagonists |
PCT/EP2012/076147 WO2013092711A1 (en) | 2011-12-19 | 2012-12-19 | Trpm8 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120403T1 true CY1120403T1 (el) | 2019-07-10 |
Family
ID=47520061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100717T CY1120403T1 (el) | 2011-12-19 | 2018-07-10 | Ανταγωνιστες trpm8 |
Country Status (22)
Country | Link |
---|---|
US (2) | US9585875B2 (el) |
EP (1) | EP2793883B1 (el) |
JP (2) | JP6238906B2 (el) |
KR (1) | KR102000319B1 (el) |
CN (1) | CN104220069B (el) |
AU (1) | AU2012357747B2 (el) |
CY (1) | CY1120403T1 (el) |
DK (1) | DK2793883T3 (el) |
EA (1) | EA025356B1 (el) |
ES (1) | ES2676884T3 (el) |
HK (1) | HK1203810A1 (el) |
HR (1) | HRP20181086T1 (el) |
HU (1) | HUE038407T2 (el) |
LT (1) | LT2793883T (el) |
ME (1) | ME03038B (el) |
PL (1) | PL2793883T3 (el) |
PT (1) | PT2793883T (el) |
RS (1) | RS57389B1 (el) |
SI (1) | SI2793883T1 (el) |
TR (1) | TR201808861T4 (el) |
WO (1) | WO2013092711A1 (el) |
ZA (1) | ZA201404499B (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2481727A1 (en) * | 2011-01-28 | 2012-08-01 | Dompe S.p.A. | TRPM8 receptor antagonists |
TR201808861T4 (tr) | 2011-12-19 | 2018-07-23 | Dompe Farm Spa | TRPM8 antagonistleri. |
EP3003292B1 (en) * | 2013-05-24 | 2019-03-20 | Nestec S.A. | Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin |
ES2747810T3 (es) | 2014-06-05 | 2020-03-11 | Bayer Cropscience Ag | Compuestos bicíclicos como agentes para combatir parásitos |
LT3157918T (lt) | 2014-06-23 | 2019-05-27 | Dompé Farmaceutici S.P.A. | 2-aril-4-hidroksi-1,3-tiazolo dariniai, tinkami naudoti kaip trpm8-inhibitoriai neuralgijos, skausmo, lėtinės obstrukcinės plaučių ligos (lopl) ar astmos gydymui |
MX2018004049A (es) * | 2015-10-01 | 2018-09-28 | Senomyx Inc | Compuestos utiles como moduladores de canal receptor 8 de potencial transitorio de melastatina (trpm8). |
EP3184524A1 (en) * | 2015-12-21 | 2017-06-28 | Dompé farmaceutici S.p.A. | 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists |
US10993939B2 (en) | 2016-06-13 | 2021-05-04 | Mitsubishi Tanabe Pharmaceutical Company | Compositions for treating or preventing vasomotor symptoms |
WO2018117166A1 (ja) * | 2016-12-21 | 2018-06-28 | キッセイ薬品工業株式会社 | チアゾール誘導体、またはその薬理学的に許容される塩 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2713573A1 (de) * | 1977-03-28 | 1978-10-05 | Basf Ag | 4,5-disubstituierte thiazole und verfahren zu ihrer herstellung |
JPS59220687A (ja) * | 1983-05-30 | 1984-12-12 | 株式会社日立製作所 | 直接サイクル型軽水原子炉一次冷却系の腐食環境抑制設備 |
KR100221041B1 (ko) * | 1990-11-30 | 1999-09-15 | 야스이 쇼사꾸 | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 |
DE60221627D1 (de) * | 2001-12-21 | 2007-09-20 | Virochem Pharma Inc | Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren |
EP1802600A1 (en) | 2004-10-13 | 2007-07-04 | Bayer HealthCare AG | Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders |
WO2007017094A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted benzyloxy-phenylmethylcarbamate derivatives |
WO2007017093A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted 2-benzyloxy-benzoic acid amide derivatives |
WO2007017092A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted 4-benzyloxy-benzoic acid amide derivatives |
WO2007080109A1 (en) | 2006-01-16 | 2007-07-19 | Bayer Healthcare Ag | Substituded benzyloxy-phenylmethylurea derivatives |
WO2007089031A1 (en) * | 2006-02-01 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Piperidine derivatives as tachykinin receptor antagonists |
CA2651865C (en) | 2006-05-10 | 2015-11-24 | Janssen Pharmaceutica N.V. | Cold menthol receptor-1 antagonists |
WO2009012430A1 (en) | 2007-07-18 | 2009-01-22 | Janssen Pharmaceutica N.V. | Sulfonamides as trpm8 modulators |
US8148422B2 (en) | 2008-12-18 | 2012-04-03 | Janssen Pharmaceutica, Nv | Sulfonamides as TRPM8 modulators |
WO2010103381A1 (en) | 2009-03-13 | 2010-09-16 | Glenmark Pharmaceuticals S.A. | Spirocyclic piperidine derivatives as trpm 8 modulators |
MX2011011428A (es) * | 2009-05-01 | 2011-11-29 | Raqualia Pharma Inc | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. |
WO2012036233A1 (ja) * | 2010-09-17 | 2012-03-22 | 塩野義製薬株式会社 | メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体 |
TR201808861T4 (tr) | 2011-12-19 | 2018-07-23 | Dompe Farm Spa | TRPM8 antagonistleri. |
-
2012
- 2012-12-19 TR TR2018/08861T patent/TR201808861T4/tr unknown
- 2012-12-19 HU HUE12812229A patent/HUE038407T2/hu unknown
- 2012-12-19 CN CN201280069993.7A patent/CN104220069B/zh active Active
- 2012-12-19 ES ES12812229.8T patent/ES2676884T3/es active Active
- 2012-12-19 LT LTEP12812229.8T patent/LT2793883T/lt unknown
- 2012-12-19 WO PCT/EP2012/076147 patent/WO2013092711A1/en active Application Filing
- 2012-12-19 PL PL12812229T patent/PL2793883T3/pl unknown
- 2012-12-19 AU AU2012357747A patent/AU2012357747B2/en active Active
- 2012-12-19 EA EA201491213A patent/EA025356B1/ru unknown
- 2012-12-19 PT PT128122298T patent/PT2793883T/pt unknown
- 2012-12-19 SI SI201231328T patent/SI2793883T1/en unknown
- 2012-12-19 US US14/366,796 patent/US9585875B2/en active Active
- 2012-12-19 ME MEP-2018-177A patent/ME03038B/me unknown
- 2012-12-19 RS RS20180793A patent/RS57389B1/sr unknown
- 2012-12-19 EP EP12812229.8A patent/EP2793883B1/en active Active
- 2012-12-19 KR KR1020147019697A patent/KR102000319B1/ko active IP Right Grant
- 2012-12-19 DK DK12812229.8T patent/DK2793883T3/en active
- 2012-12-19 JP JP2014547975A patent/JP6238906B2/ja active Active
-
2014
- 2014-06-19 ZA ZA2014/04499A patent/ZA201404499B/en unknown
-
2015
- 2015-03-25 HK HK15103054.0A patent/HK1203810A1/xx unknown
-
2017
- 2017-01-25 US US15/414,803 patent/US9856246B2/en active Active
- 2017-06-19 JP JP2017119493A patent/JP2017197564A/ja not_active Withdrawn
-
2018
- 2018-07-10 CY CY20181100717T patent/CY1120403T1/el unknown
- 2018-07-11 HR HRP20181086TT patent/HRP20181086T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US20170129881A1 (en) | 2017-05-11 |
TR201808861T4 (tr) | 2018-07-23 |
KR102000319B1 (ko) | 2019-09-27 |
HK1203810A1 (en) | 2015-11-06 |
AU2012357747A2 (en) | 2014-08-21 |
AU2012357747A1 (en) | 2014-07-10 |
SI2793883T1 (en) | 2018-08-31 |
KR20150000870A (ko) | 2015-01-05 |
AU2012357747B2 (en) | 2017-09-07 |
HUE038407T2 (hu) | 2018-10-29 |
ZA201404499B (en) | 2015-12-23 |
JP2015504874A (ja) | 2015-02-16 |
JP6238906B2 (ja) | 2017-11-29 |
HRP20181086T1 (hr) | 2018-09-07 |
LT2793883T (lt) | 2018-08-10 |
CN104220069A (zh) | 2014-12-17 |
JP2017197564A (ja) | 2017-11-02 |
US20140371276A1 (en) | 2014-12-18 |
PT2793883T (pt) | 2018-07-18 |
AU2012357747A8 (en) | 2014-07-24 |
ME03038B (me) | 2018-10-20 |
PL2793883T3 (pl) | 2018-09-28 |
DK2793883T3 (en) | 2018-07-30 |
WO2013092711A1 (en) | 2013-06-27 |
US9856246B2 (en) | 2018-01-02 |
EA201491213A1 (ru) | 2014-11-28 |
US9585875B2 (en) | 2017-03-07 |
EA025356B1 (ru) | 2016-12-30 |
ES2676884T3 (es) | 2018-07-25 |
CN104220069B (zh) | 2018-10-02 |
RS57389B1 (sr) | 2018-09-28 |
EP2793883B1 (en) | 2018-04-18 |
EP2793883A1 (en) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120403T1 (el) | Ανταγωνιστες trpm8 | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1120834T1 (el) | Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1 | |
CY1120172T1 (el) | Αναστολεις κινασων σερινης/θρεονινης | |
CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
CY1120846T1 (el) | 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1 | |
CY1117743T1 (el) | Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης | |
CY1119843T1 (el) | Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης | |
CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
BR112016025423A2 (pt) | compostos e composições como agonistas de receptores do tipo toll 7 | |
MA32975B1 (fr) | Antagonistes de c5ar | |
CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
CY1118362T1 (el) | Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης | |
CL2008001705A1 (es) | Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3. | |
CO6351782A2 (es) | COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA | |
EA200901263A1 (ru) | Конденсированный аминопиридин в качестве ингибиторов hsp90 | |
CY1119800T1 (el) | Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων | |
CY1121137T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3 | |
UY32820A (es) | Composiciones dermatologicas de antagonistas del receptor dp2 | |
CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 | |
CY1117706T1 (el) | Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac | |
CY1123231T1 (el) | Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο | |
PA8795601A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
CY1114023T1 (el) | Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog |